MAIA Study Outcomes
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine provides outcomes from the MAIA study that co... Author: obr Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts

IV Daratumumab versus Subcutaneous Daratumumab
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine, compares intravenous daratumumab versus subc... Author: obr Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts

KEYNOTE-365 in mCRPC Results
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the results of KEYNOTe-365, pembrolizumab in metastatic castration-resistant prostate cancer ... Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

Upcoming Prostate Cancer PARP Inhibitor Trials
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai shares details on upcoming prostate cancer PARP inhibitor trials. <br /> Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

The Role of Biomarker Selection Trials in Prostate Cancer
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai elaborates on how biomarker selection trials may help identify in prostate cancer patients. Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

Difference in ENZAMET and TITAN Studies
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the differences between the ENZAMET and TITAN studies. <br /> Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

Outcomes from the TITAN Study in mCSPC
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai discusses the outcomes of the TITAN study in metastatic castration-sensitive prostate cancer (mCSPC).<br />... Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

CLL14 Trial Outcomes
Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health shares details on the CLL14 trial in chronic lymphocytic leukemia (CLL) that wa... Author: obr Added: 06/27/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2019 Category: Cancer & Oncology Source Type: podcasts

CAR-T Cell Therapy May Be Combined to Treat Lymphoma
Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health considers how CAR-T cell therapy may be combined to treat lymphomas Author: obr Added: 06/27/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2019 Category: Cancer & Oncology Source Type: podcasts

Impact of CAR-T Cell Therapy in the Treatment of B-Cell Lymphoma
Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health discusses how impactful CAR-T cell therapy has been for the treatment of B-cell... Author: obr Added: 06/27/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2019 Category: Cancer & Oncology Source Type: podcasts

Data on Umbralisib in Relapsed/Refractory Lymphoma
Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health explains the results of the umbralisib phase II study involving patients with r... Author: obr Added: 06/27/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2019 Category: Cancer & Oncology Source Type: podcasts